Table 3.
Characteristics of studies in OS, DFS/RFS group in this meta-analysis.
| First author | Year | Country | Cancer type | Clinical stage | Samples | Cut off | Follow-up (month) | Method | Outcome | Analysis | HR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D'Alterio C | 2010 | Italy | RCC | I-IV | 170 | >20% | 3-180 | IHC | DFS | U/M | Reported |
| Yao X | 2011 | China | GBC | I-IV | 72 | Score≥2 | 3-120 | IHC | OS | M | Reported |
| Schrevel M | 2012 | The Netherlands | CC | NA | 101 | positive | 137 (5-266) | IHC | DFS | U | Reported |
| Wang L | 2012 | China | RCC | I-IV | 97 | ≥25% | 120 | IHC | OS/RFS | U/M | Reported |
| D'Alterio C | 2013 | Italy | CRC | I-III | 64 | >50% | 60 | IHC | RFS | U | Reported |
| Polimeno M (tc) | 2014 | Italy | HCC | I-IV | 80 | ≥60% | 126 | IHC | OS | U | Reported |
| Polimeno M (vc) | 2014 | Italy | HCC | I-IV | 39 | ≥60% | 87 | IHC | OS | U | Reported |
| Xue T (H) | 2014 | China | HCC | NA | 74 | High | 110 | IHC | OS/RFS | U | SC |
| Xue T (EH) | 2014 | China | HCC | NA | 48 | High | 110 | IHC | OS/RFS | U | SC |
| Birner P | 2015 | Austria | Glioma | NA | 37 | positive | 52 | IHC | OS | U | Reported |
| Li G | 2015 | China | CS | I-III | 60 | ≥10% | 60 | IHC | OS | U | SC |
| Yang D | 2015 | China | CRC | I-IV | 96 | Score≥2 | 60 | IHC | OS | M | Reported |
| Goto M | 2015 | Japan | ESCC | I-IV | 113 | ≥1+ | 94 | IHC | RFS | U | SC |
| Guo J | 2016 | China | PC | NA | 232 | Score4-9 | 2-87 | IHC | OS | M | SC |
| Deng L | 2017 | China | GBM | NA | 146 | High | 120 | IHC | OS | M | Reported |
| Qiao Y | 2017 | China | ESCC | I-IV | 45 | High | 45 | IHC | OS | U | SC |
Abbreviations: NSCLC, nonsmall cell lung cancer; CC cervical cancer; PC, pancreatic cancer; tc, training cohort; vc, validation cohort; H, low HNF4α expression; EH, Edmondson grade 1/2 and low HNF4α expression, U, univariate analysis; M, multivariate analysis; SC: survival